Pfizer Gets Final EU Approval For Biosimilar Bevacizumab
Pfizer has received a pan-European marketing authorization for its Zirabev biosimilar bevacizumab, a rival to Genentech’s Avastin. The nod marks Pfizer’s second European approval for an oncology biosimilar.
You may also be interested in...
Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.
Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.
Pfizer has secured FDA approval for its Zirabev becacizumab biosimilar. But Genentech is citing 22 patents it says should bar the rival to its Avastin oncology brand.